參考文獻/References:
[1] HUANG C,WEN Z,NIU J,et al.Steroid-induced osteonecrosis of the femoral head:novel insight into the roles of bone endothelial cells in pathogenesis and treatment[J/OL].Front Cell Dev Biol,2021,9:777697[2022-05-02].https://pubmed.ncbi.nlm.nih.gov/34917616/.
[2] CHANG C,GREENSPAN A,GERSHWIN M E.The pathogenesis,diagnosis and clinical manifestations of steroid-induced osteonecrosis[J/OL].J Autoimmun,2020,110:102460[2022-05-02].https://pubmed.ncbi.nlm.nih.gov/32307211/.
[3] IKEUCHI K,HASEGAWA Y,SEKI T,et al.Epidemiology of nontraumatic osteonecrosis of the femoral head in Japan[J].Mod Rheumatol,2015,25(2):278-281.
[4] FANG S,LI Y,CHEN P.Osteogenic effect of bone marrow mesenchymal stem cell-derived exosomes on steroid-induced osteonecrosis of the femoral head[J].Drug Des Devel Ther,2018,13:45-55.
[5] 朱佩軒.伏邪源流及理論發(fā)微[J].亞太傳統(tǒng)醫(yī)藥,2021,17(7):194-196.
[6] 張晨晨,唐樹杰.伏邪理論與運氣理論[J].中華中醫(yī)藥雜志,2021,36(5):2597-2600.
[7] 趙明芬,安冬青,汪建萍.試論伏邪理論的源流及發(fā)展[J].中醫(yī)雜志,2016,57(3):189-192.
[8] 曾治君,鄭恬,吉燕華,等.伏邪理論的探討[J].中西醫(yī)結合心血管病電子雜志,2017,5(29):159-160.
[9] 吳文軍,劉西洋,馮全生,等.試論伏氣學說之“伏”[J].中華中醫(yī)藥雜志,2021,36(10):5804-5806.
[10] VANDEWALLE J,LUYPAERT A,DE BOSSCHER K,et al.Therapeutic mechanisms of glucocorticoids[J].Trends Endocrinol Metab,2018,29(1):42-54.
[11] ORAY M,ABU SAMRA K,EBRAHIMIADIB N,et al.Long-term side effects of glucocorticoids[J].Expert Opin Drug Saf,2016,15(4):457-465.
[12] 吳斌.糖皮質(zhì)激素副作用的中醫(yī)藥研究進展[J].時珍國醫(yī)國藥,2010,21(3):719-721.
[13] 張金良,王憲波,曾輝.從中醫(yī)學角度談糖皮質(zhì)激素副作用的藥理機制[J].北京中醫(yī)藥,2010,29(4):276-279.
[14] 劉芬芬,羊維,黃琳,等.中醫(yī)學對糖皮質(zhì)激素主治功效的藥性認識[J].中華中醫(yī)藥雜志,2015,30(4):1268-1270.
[15] CIMINO I,KIM H,TUNG Y C L,et al.Activation of the hypothalamic-pituitary-adrenal axis by exogenous and endogenous GDF15[J/OL].Proc Natl Acad Sci U S A,2021,118(27):e2106868118[2022-05-02].https://pubmed.ncbi.nlm.nih.gov/34187898/.
[16] ALTEN R,WIEBE E.Hypothalamic-pituitary-adrenal axis function in patients with rheumatoid arthritis treated with different glucocorticoid approaches[J].Neuroimmunomodulation,2015,22(1-2):83-88.
[17] XU T T,JIN H T,TONG P J.Essence of“shen(kidney)controlling bones”:conceptual analysis based on hypothalamic-pituitary-adrenal-osteo-related cells axis[J].Chin J Integr Med,2018,24(11):806-808.
[18] 曾思敏,梁琪,韋靜,等.黃貴華從中醫(yī)學角度論治糖皮質(zhì)激素不良反應[J].上海中醫(yī)藥雜志,2019,53(7):18-20.
[19] 徐宇,黃維琛,郭禮躍,等.補腎運脾方對糖皮質(zhì)激素性骨質(zhì)疏松斑馬魚模型骨代謝的調(diào)節(jié)作用[J].中藥藥理與臨床,2019,35(3):138-141.
[20] 溫成平,謝志軍.激素不同使用階段的中醫(yī)證候診斷和治療指南[J].中華中醫(yī)藥雜志,2020,35(9):4536-4540.
[21] 尚奇,任輝,沈耿楊,等.基于腎陰陽理論探討自噬在激素性骨質(zhì)疏松癥中的作用[J].中華中醫(yī)藥雜志,2018,33(8):3300-3303.
[22] LANE N E.Glucocorticoid-induced osteoporosis:new insights into the pathophysiology and treatments[J].Curr Osteoporos Rep,2019,17(1):1-7.
[23] WEINSTEIN R S.Glucocorticoids,osteocytes,and skeletal fragility:the role of bone vascularity[J].Bone,2010,46(3):564-570.
[24] SCHERHOLZ M L,SCHLESINGER N,ANDROULAKIS I P.Chronopharmacology of glucocorticoids[J].Adv Drug Deliv Rev,2019,151-152:245-261.
[25] RODRIGUEZ J M,MONSALVES-ALVAREZ M,HENRIQUEZ S,et al.Glucocorticoid resistance in chronic diseases[J].Steroids,2016,115:182-192.
[26] 馮炯,周東海,臧敏,等.從伏邪學說論治系統(tǒng)性紅斑狼瘡[J].中華中醫(yī)藥雜志,2019,34(10):4659-4661.
[27] TAN B,LI W,ZENG P,et al.Epidemiological study based on china osteonecrosis of the femoral head database[J].Orthop Surg,2021,13(1):153-160.
[28] WANG A,REN M,WANG J.The pathogenesis of steroid-induced osteonecrosis of the femoral head:a systematic review of the literature[J].Gene,2018,671:103-109.
[29] ZHAO Z,ZHANG L,KANG X,et al.Association between genetic polymorphisms of CR2 gene and the risk of steroid-induced osteonecrosis of the femoral head in the Chinese Han male population[J].Genet Test Mol Biomarkers,2020,24(8):460-466.
[30] GUERADO E,CASO E.The physiopathology of avascular necrosis of the femoral head:an update[J].Injury,2016,47 Suppl 6:S16-S26.
[31] NICKOLAS T L,JAMAL S A.Bone kidney interactions[J].Rev Endocr Metab Disord,2015,16(2):157-163.
[32] 李坤寧,張慶祥,徐成巖,等.伏邪病因病機特點的探析[J].中國中醫(yī)急癥,2019,28(12):2170-2173.
[33] 張應拴,邢濤,李盛華,等.名中醫(yī)治療股骨頭壞死的用藥規(guī)律分析[J].中醫(yī)正骨,2021,33(9):73-75.
[34] 袁雪超,路玉峰,魯超,等.龍元通絡生骨顆粒治療早期激素性股骨頭壞死40例[J].中國中醫(yī)骨傷科雜志,2021,29(3):70-74.
[35] 魏秋實,李子祺,袁穎嘉,等.“標本兼治”理論在股骨頭壞死中醫(yī)藥治療中的指導作用[J].中醫(yī)正骨,2020,32(1):56-59.
[36] 于潼,謝利民,張振南,等.股骨頭壞死中醫(yī)體質(zhì)分布研究[J].中國中西醫(yī)結合雜志,2016,36(6):659-662.
[37] 李非,李盛華,周明旺,等.激素性股骨頭壞死發(fā)病機制中醫(yī)理論探析及中醫(yī)體質(zhì)研究現(xiàn)狀[J].西部中醫(yī)藥,2018,31(2):135-137.
[38] 魏秋實,何偉,張慶文,等.基于中醫(yī)治未病理論探討新型冠狀病毒肺炎后股骨頭壞死的防治思路[J].中醫(yī)正骨,2020,32(3):48-51.
(收稿日期:2022-05-03 本文編輯:郭毅曼)
相似文獻/References:
[1]陳雷雷,張穎.何偉教授采用中醫(yī)藥療法治療股骨頭壞死的經(jīng)驗[J].中醫(yī)正骨,2015,27(10):74.
[2]徐西林,趙永蘭,張曉峰,等.活骨注射液髖關節(jié)腔灌注對兔股骨頭壞死模型
血管內(nèi)皮生長因子表達的動態(tài)影響[J].中醫(yī)正骨,2015,27(08):1.
XU Xilin,ZHAO Yonglan,ZHANG Xiaofeng,et al.Dynamic effect of intra-articular hip injection of Huogu injection on the expression of vascular endothelial growth factor in rabbit models with femur head necrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(02):1.
[3]周勇,任菲菲,豐凡翔,等.血管內(nèi)皮生長因子和骨形態(tài)發(fā)生蛋白2
在非創(chuàng)傷性股骨頭壞死不同區(qū)域的表達[J].中醫(yī)正骨,2015,27(08):7.
ZHOU Yong,REN Feifei,FENG Fanxiang,et al.Expressions of vascular endothelial growth factor and bone morphogenetic protein 2 in different zones of femoral head with non-traumatic osteonecrosis[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(02):7.
[4]鮑榮華,王國平,夏曉斌,等.鉭棒植入治療非創(chuàng)傷性股骨頭壞死的療效觀察[J].中醫(yī)正骨,2015,27(02):28.
[5]張兵,馬凰富,劉波,等.非創(chuàng)傷性股骨頭壞死的舌象定量研究[J].中醫(yī)正骨,2015,27(04):8.
ZHANG Bing,MA Huangfu,LIU Bo,et al.Quantitative study on tongue manifestation of patients with nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(02):8.
[6]李剛,程春生.股骨頭壞死血瘀證癥狀與平樂郭氏正骨方藥藥物組成
最大頻繁關聯(lián)模式挖掘[J].中醫(yī)正骨,2015,27(04):21.
LI Gang,CHENG Chunsheng.Maximal frequent association pattern mining for studying the relationship between BLOOD STASIS syndrome in patients with osteonecrosis of femoral head and drug components of Pingle Guo's orthopedics prescription[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2015,27(02):21.
[7]李文龍,梅沉成,杜貴強,等.微創(chuàng)減壓植骨多孔鉭棒植入治療
ARCOⅡ期非創(chuàng)傷性缺血性股骨頭壞死[J].中醫(yī)正骨,2016,28(02):43.
[8]張磊,金紅婷,童培建.骨健口服液早期干預非創(chuàng)傷性股骨頭壞死的臨床研究[J].中醫(yī)正骨,2016,28(03):14.
ZHANG Lei,JIN Hongting,TONG Peijian.Clinical study on Gujian Koufuye(骨健口服液)for early intervention of nontraumatic osteonecrosis of femoral head[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(02):14.
[9]鮑榮華,王國平,夏曉斌,等.直接前入路微創(chuàng)全髖關節(jié)置換術治療晚期股骨頭壞死[J].中醫(yī)正骨,2016,28(03):61.
[10]張超,姚晨,沈計榮.微創(chuàng)髓芯減壓打壓支撐植骨術結合補腎活血湯口服治療ARCOⅡ、Ⅲ期股骨頭壞死的近期療效觀察[J].中醫(yī)正骨,2016,28(03):20.
ZHANG Chao,YAO Chen,SHEN Jirong.[J].The Journal of Traditional Chinese Orthopedics and Traumatology,2016,28(02):20.